Navamedic ASA Launches Eroxon® in Sweden: A Fast and Safe Treatment for Erectile Dysfunction
Navamedic ASA, a leading Nordic pharma company, has introduced Eroxon® in the Swedish market. Eroxon® is a groundbreaking non-prescription treatment for erectile dysfunction that has already gained popularity in Norway since its launch in February 2024. With a fast-acting gel formula, Eroxon® is designed to improve men’s sexual health and quality of life.
Eroxon® is proving to be a game-changer in the treatment of erectile dysfunction, with strong sales and positive consumer feedback in Norway. It is currently one of Navamedic’s top-selling products in the Consumer Health segment. The launch in Sweden is expected to have even greater growth potential, as Eroxon® will be the only non-prescription treatment available in the market.
According to a recent survey conducted on behalf of Navamedic, four out of ten men in Sweden have experienced erectile dysfunction at some point. However, many do not seek help due to the stigma associated with the condition. Eroxon® aims to address this issue by offering an easily accessible and effective solution for men seeking treatment.
Eroxon® stands out from other erectile dysfunction treatments due to its rapid onset of action, with men typically experiencing results within ten minutes. Its local mechanism of action minimizes systemic absorption, making it safe for use. The product is approved for the treatment of erectile dysfunction in both the EU and the US.
“We are excited to bring Eroxon® to the Swedish market and provide men with a safe and reliable solution for erectile dysfunction. Our goal is to help improve the quality of life for men who may be hesitant to seek treatment. We are confident that Eroxon® will be well-received in Sweden, just as it has been in Norway and the UK,” says Jack Spira, Medical Director at Navamedic.
For more information about Eroxon® and Navamedic ASA, please visit the official website or contact Kathrine Gamborg Andreassen, CEO of Navamedic, at +47 951 78 680.
This press release was provided by Navamedic ASA and distributed via Cision. For media inquiries, please visit https://news.cision.com/navamedic-asa/r/navamedic-asa–broad-launch-for-eroxon–in-sweden-today,c3973679.
Source link
